TOP 100 USA DRUG COST PER
PATIENT PER YEAR 2012-2016
Average Orphan Drug Cost to Patients $140,443 in 2016; Median
Orphan Drug Cost $83,883
The average cost per patient per
year in 2016 for an orphan drug
was $140,443 versus $27,756 for a
non-orphan drug. The average drug
price has increased year on year
for both orphan and non-orphan
drugs since 2012. The median price
differential between an orphan and
non-orphan drug in 2016 was 5. 5
compared to 9. 8 in 2012.
The median price of orphan drugs
and non-orphan drugs has increased by a factor of 1.3 and 2.3
since 2012 respectively.
[See orphan drug charts 2 & 3]
2016: USA REVENUE PER
PATIENT PER YEAR FOR TOP
20 SELLING ORPHAN DRUGS
Soliris will be the Highest Revenue
Orphan Drug in 2016
Revenue per patient for the Top 20
USA selling orphan drugs is correlated (R2 = 0.77) to the number of
patients treated in 2016. A similar
analysis of the Top 10 selling orphan drugs that treated fewer than
10,000 patients confirms a closer
correlation (R2 = 0.94). This analysis confirms industry perceptions
that smaller patient groups allow
a pricing premium to be achieved
versus non-orphans. Products such
as Gleevec support the notion of an
innovation premium for drugs that
create a step change in treatment
options and therapy outcomes.
Soliris confirms the pricing power
resulting from indications with the
fewest number of patients.
[See orphan drug charts 4 & 5]
Orphan drug chart 3
Note: Cost per patient is an estimate for the retail cost of a drug to a patient,
for a given year, based on a 100% compliance to the treatment guidelines
outlined in the FDA label. Does not include off-invoice discounts. The Top
100 orphan and non-orphan drugs were ranked by USA sales for 2016.
Prices for products in the US are sourced from Medicare Part B, NADAC,
FSS and Medicaid. Availability of a price point determines choice of source.
The source is kept consistent across years to reflect a clear trend in pricing.
